Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01-12-2021 | Acute Myeloid Leukemia | Review

BH3-mimetics: recent developments in cancer therapy

Authors: Paul A. Townsend, Maria V. Kozhevnikova, Olivier N. F. Cexus, Andrey A. Zamyatnin Jr, Surinder M. Soond

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2021

Login to get access

Abstract

The hopeful outcomes from 30 years of research in BH3-mimetics have indeed served a number of solid paradigms for targeting intermediates from the apoptosis pathway in a variety of diseased states. Not only have such rational approaches in drug design yielded several key therapeutics, such outputs have also offered insights into the integrated mechanistic aspects of basic and clinical research at the genetics level for the future. In no other area of medical research have the effects of such work been felt, than in cancer research, through targeting the BAX-Bcl-2 protein-protein interactions. With these promising outputs in mind, several mimetics, and their potential therapeutic applications, have also been developed for several other pathological conditions, such as cardiovascular disease and tissue fibrosis, thus highlighting the universal importance of the intrinsic arm of the apoptosis pathway and its input to general tissue homeostasis. Considering such recent developments, and in a field that has generated so much scientific interest, we take stock of how the broadening area of BH3-mimetics has developed and diversified, with a focus on their uses in single and combined cancer treatment regimens and recently explored therapeutic delivery methods that may aid the development of future therapeutics of this nature.
Literature
1.
2.
Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ. 2018;25(1):27–36.PubMedCrossRef
3.
Ashkenazi A, Fairbrother WJ, Leverson JD, Souers AJ. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors. Nat Rev Drug Discov. 2017;16(4):273–84.PubMedCrossRef
4.
Soond SM, Kozhevnikova MV, Savvateeva LV, Townsend PA, Zamyatnin AA Jr. Intrinsically connected: therapeutically targeting the cathepsin proteases and the Bcl-2 family of protein substrates as co-regulators of apoptosis. Int J Mol Sci. 2021;22(9):4669.PubMedPubMedCentralCrossRef
5.
Merino D, Kelly GL, Lessene G, Wei AH, Roberts AW, Strasser A. BH3-mimetic drugs: blazing the Trail for new Cancer medicines. Cancer Cell. 2018;34(6):879–91.PubMedCrossRef
6.
Rampino N, Yamamoto H, Ionov Y, Li Y, Sawai H, Reed JC, et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science. 1997;275(5302):967–9.PubMedCrossRef
7.
Zhang M, Zheng J, Nussinov R, Ma B. Oncogenic mutations differentially affect Bax monomer, dimer, and oligomeric pore formation in the membrane. Sci Rep. 2016;6:33340.PubMedPubMedCentralCrossRef
8.
Shibata MA, Liu ML, Knudson MC, Shibata E, Yoshidome K, Bandey T, et al. Haploid loss of bax leads to accelerated mammary tumor development in C3(1)/SV40-TAg transgenic mice: reduction in protective apoptotic response at the preneoplastic stage. EMBO J. 1999;18(10):2692–701.PubMedPubMedCentralCrossRef
9.
Kaiser U, Schilli M, Haag U, Neumann K, Kreipe H, Kogan E, et al. Expression of bcl-2--protein in small cell lung cancer. Lung Cancer. 1996;15(1):31–40.PubMedCrossRef
10.
Delbridge AR, Grabow S, Strasser A, Vaux DL. Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies. Nat Rev Cancer. 2016;16(2):99–109.PubMedCrossRef
11.
Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene. 1995;11(7):1389–94.PubMed
12.
Findley HW, Gu L, Yeager AM, Zhou M. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 1997;89(8):2986–93.PubMedCrossRef
13.
14.
Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW. BH3-only proteins: orchestrators of apoptosis. Biochim Biophys Acta. 2011;1813(4):508–20.PubMedCrossRef
15.
16.
17.
Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479–89.PubMedCrossRef
18.
Schuler M, Green DR. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans. 2001;29(Pt 6):684–8.PubMedCrossRef
19.
Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010;330(6009):1390–3.PubMedPubMedCentralCrossRef
20.
Villunger A, Labi V, Bouillet P, Adams J, Strasser A. Can the analysis of BH3-only protein knockout mice clarify the issue of 'direct versus indirect' activation of Bax and Bak? Cell Death Differ. 2011;18(10):1545–6.PubMedPubMedCentralCrossRef
21.
Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell. 2001;8(3):705–11.PubMedCrossRef
22.
Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science. 2007;315(5813):856–9.PubMedCrossRef
23.
Chen HC, Kanai M, Inoue-Yamauchi A, Tu HC, Huang Y, Ren D, et al. An interconnected hierarchical model of cell death regulation by the BCL-2 family. Nat Cell Biol. 2015;17(10):1270–81.PubMedPubMedCentralCrossRef
24.
Du H, Wolf J, Schafer B, Moldoveanu T, Chipuk JE, Kuwana T. BH3 domains other than Bim and bid can directly activate Bax/Bak. J Biol Chem. 2011;286(1):491–501.PubMedCrossRef
25.
Gallenne T, Gautier F, Oliver L, Hervouet E, Noel B, Hickman JA, et al. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol. 2009;185(2):279–90.PubMedPubMedCentralCrossRef
26.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.PubMedPubMedCentralCrossRef
27.
Warr MR, Shore GC. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med. 2008;8(2):138–47.PubMedCrossRef
28.
Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005;19(11):1294–305.PubMedPubMedCentralCrossRef
29.
Zhong Q, Gao W, Du F, Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell. 2005;121(7):1085–95.PubMedCrossRef
30.
Nakajima W, Tanaka N. Synergistic induction of apoptosis by p53-inducible Bcl-2 family proteins Noxa and Puma. J Nippon Med Sch. 2007;74(2):148–57.PubMedCrossRef
31.
Nakajima W, Tanaka N. Noxa induces apoptosis in oncogene-expressing cells through catch-and-release mechanism operating between Puma and Mcl-1. Biochem Biophys Res Commun. 2011;413(4):643–8.PubMedCrossRef
32.
Varadarajan S, Vogler M, Butterworth M, Dinsdale D, Walensky LD, Cohen GM. Evaluation and critical assessment of putative MCL-1 inhibitors. Cell Death Differ. 2013;20(11):1475–84.PubMedPubMedCentralCrossRef
33.
Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res. 2007;13(7):2144–50.PubMedCrossRef
34.
Masilamani AP, Dettmer-Monaco V, Monaco G, Cathomen T, Kuckuck I, Schultze-Seemann S, et al. An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and specifically induces in combination with the bad-like BH3 Mimetic ABT-737 apoptosis in prostate cancer cells. Cancers (Basel). 2020;12(6):1648.CrossRef
35.
Wu H, Schiff DS, Lin Y, Neboori HJ, Goyal S, Feng Z, et al. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Radiat Res. 2014;182(6):618–25.PubMedPubMedCentralCrossRef
36.
Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053–8.PubMedCrossRef
37.
Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell. 2001;7(3):683–94.PubMedCrossRef
38.
Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell. 2001;7(3):673–82.PubMedCrossRef
39.
Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102(1):33–42.PubMedCrossRef
40.
Philchenkov A, Miura K. The IAP protein family, SMAC mimetics and Cancer treatment. Crit Rev Oncog. 2016;21(3–4):185–202.PubMedCrossRef
41.
Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57.PubMedPubMedCentralCrossRef
42.
Fraser C, Ryan J, Sarosiek K. BH3 profiling: a functional assay to measure apoptotic priming and dependencies. Methods Mol Biol. 1877;2019:61–76.
43.
Villalobos-Ortiz M, Ryan J, Mashaka TN, Opferman JT, Letai A. BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics. Cell Death Differ. 2020;27(3):999–1007.PubMedCrossRef
44.
Bhola PD, Ahmed E, Guerriero JL, Sicinska E, Su E, Lavrova E, et al. High-throughput dynamic BH3 profiling may quickly and accurately predict effective therapies in solid tumors. Sci Signal. 2020;13(636):eaay1451.PubMedPubMedCentralCrossRef
45.
Cosulich SC, Worrall V, Hedge PJ, Green S, Clarke PR. Regulation of apoptosis by BH3 domains in a cell-free system. Curr Biol. 1997;7(12):913–20.PubMedCrossRef
46.
Holinger EP, Chittenden T, Lutz RJ. Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J Biol Chem. 1999;274(19):13298–304.PubMedCrossRef
47.
Chin JW, Schepartz A. Design and evolution of a miniature Bcl-2 binding protein. Angew Chem Int Ed Engl. 2001;40(20):3806–9.PubMedCrossRef
48.
Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther. 2013;12(9):1691–700.PubMedCrossRef
49.
Baell JB, Huang DC. Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochem Pharmacol. 2002;64(5–6):851–63.PubMedCrossRef
50.
Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, et al. Crystal structure of ABT-737 complexed with Bcl-xL: implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ. 2007;14(9):1711–3.PubMedCrossRef
51.
Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435(7042):677–81.PubMedCrossRef
52.
Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem. 2003;46(20):4259–64.PubMedCrossRef
53.
Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, et al. Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci U S A. 2000;97(13):7124–9.PubMedPubMedCentralCrossRef
54.
Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, et al. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol. 2001;3(2):173–82.PubMedCrossRef
55.
Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, et al. Antimycin a mimics a cell-death-inducing Bcl-2 homology domain 3. Nat Cell Biol. 2001;3(2):183–91.PubMedCrossRef
56.
Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, et al. Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem. 2001;44(25):4313–24.PubMedCrossRef
57.
Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD. Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J Am Chem Soc. 2002;124(40):11838–9.PubMedCrossRef
58.
Park CM, Oie T, Petros AM, Zhang H, Nimmer PM, Henry RF, et al. Design, synthesis, and computational studies of inhibitors of Bcl-XL. J Am Chem Soc. 2006;128(50):16206–12.PubMedCrossRef
59.
Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008;68(9):3421–8.PubMedCrossRef
60.
Wang G, Nikolovska-Coleska Z, Yang CY, Wang R, Tang G, Guo J, et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem. 2006;49(21):6139–42.PubMedCrossRef
61.
Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, et al. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci U S A. 2007;104(49):19512–7.PubMedPubMedCentralCrossRef
62.
Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8.PubMedCrossRef
63.
Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science. 2004;305(5689):1471–4.PubMedCrossRef
64.
Bai L, Chen W, Chen W, Wang X, Tang H, Lin Y. IKKbeta-mediated nuclear factor-kappaB activation attenuates smac mimetic-induced apoptosis in cancer cells. Mol Cancer Ther. 2009;8(6):1636–45.PubMedPubMedCentralCrossRef
65.
Lu J, Bai L, Sun H, Nikolovska-Coleska Z, McEachern D, Qiu S, et al. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res. 2008;68(22):9384–93.PubMedPubMedCentralCrossRef
66.
Cai Q, Sun H, Peng Y, Lu J, Nikolovska-Coleska Z, McEachern D, et al. A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem. 2011;54(8):2714–26.PubMedPubMedCentralCrossRef
67.
Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D, et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia. 2010;24(12):2100–9.PubMedPubMedCentralCrossRef
68.
Sun H, Nikolovska-Coleska Z, Lu J, Meagher JL, Yang CY, Qiu S, et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J Am Chem Soc. 2007;129(49):15279–94.PubMedPubMedCentralCrossRef
69.
Allensworth JL, Sauer SJ, Lyerly HK, Morse MA, Devi GR. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-alpha-independent mechanism. Breast Cancer Res Treat. 2013;137(2):359–71.PubMedCrossRef
70.
Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, et al. Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis. 2015;6:e1590.PubMedPubMedCentralCrossRef
71.
Bruncko M, Wang L, Sheppard GS, Phillips DC, Tahir SK, Xue J, et al. Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity. J Med Chem. 2015;58(5):2180–94.PubMedCrossRef
72.
Caenepeel S, Brown SP, Belmontes B, Moody G, Keegan KS, Chui D, et al. AMG 176, a selective MCL1 inhibitor, is effective in hematologic Cancer models alone and in combination with established therapies. Cancer Discov. 2018;8(12):1582–97.PubMedCrossRef
73.
Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9(1):5341.PubMedPubMedCentralCrossRef
74.
Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, et al. The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature. 2016;538(7626):477–82.PubMedCrossRef
75.
Stewart ML, Fire E, Keating AE, Walensky LD. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat Chem Biol. 2010;6(8):595–601.PubMedPubMedCentralCrossRef
76.
Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with Venetoclax rescues Venetoclax-resistant acute myelogenous leukemia. Cancer Discov. 2018;8(12):1566–81.PubMedPubMedCentralCrossRef
77.
Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, et al. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017;591(1):240–51.PubMedCrossRef
78.
Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-t hieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem. 2008;51(18):5522–32.PubMedCrossRef
79.
Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986;47(1):19–28.PubMedCrossRef
80.
Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 1985;228(4706):1440–3.PubMedCrossRef
81.
Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335(6189):440–2.PubMedCrossRef
82.
Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22(53):8590–607.PubMedCrossRef
83.
Correia C, Lee SH, Meng XW, Vincelette ND, Knorr KL, Ding H, et al. Emerging understanding of Bcl-2 biology: implications for neoplastic progression and treatment. Biochim Biophys Acta. 2015;1853(7):1658–71.PubMedPubMedCentralCrossRef
84.
85.
Tessoulin B, Papin A, Gomez-Bougie P, Bellanger C, Amiot M, Pellat-Deceunynck C, et al. BCL2-family dysregulation in B-cell malignancies: from gene expression regulation to a targeted therapy biomarker. Front Oncol. 2018;8:645.PubMedCrossRef
86.
Tracey L, Perez-Rosado A, Artiga MJ, Camacho FI, Rodriguez A, Martinez N, et al. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively. J Pathol. 2005;206(2):123–34.PubMedCrossRef
87.
Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene. 2016;35(48):6223–34.PubMedPubMedCentralCrossRef
88.
Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96(4):574–82.PubMedCrossRef
89.
Gong JN, Khong T, Segal D, Yao Y, Riffkin CD, Garnier JM, et al. Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood. 2016;128(14):1834–44.PubMedCrossRef
90.
Del Gaizo MV, Letai A. BH3 profiling--measuring integrated function of the mitochondrial apoptotic pathway to predict cell fate decisions. Cancer Lett. 2013;332(2):202–5.CrossRef
91.
Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001;292(5517):727–30.PubMedPubMedCentralCrossRef
92.
Nechushtan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J. 1999;18(9):2330–41.PubMedPubMedCentralCrossRef
93.
Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 1997;139(5):1281–92.PubMedPubMedCentralCrossRef
94.
Moldoveanu T, Liu Q, Tocilj A, Watson M, Shore G, Gehring K. The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol Cell. 2006;24(5):677–88.PubMedCrossRef
95.
Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47–59.PubMedCrossRef
96.
Dewson G, Kratina T, Sim HW, Puthalakath H, Adams JM, Colman PM, et al. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3:groove interactions. Mol Cell. 2008;30(3):369–80.PubMedCrossRef
97.
George NM, Evans JJ, Luo X. A three-helix homo-oligomerization domain containing BH3 and BH1 is responsible for the apoptotic activity of Bax. Genes Dev. 2007;21(15):1937–48.PubMedPubMedCentralCrossRef
98.
Labi V, Grespi F, Baumgartner F, Villunger A. Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy? Cell Death Differ. 2008;15(6):977–87.PubMedCrossRef
99.
van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell. 2006;10(5):389–99.PubMedPubMedCentralCrossRef
100.
Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006;10(5):375–88.PubMedCrossRef
101.
High LM, Szymanska B, Wilczynska-Kalak U, Barber N, O'Brien R, Khaw SL, et al. The Bcl-2 homology domain 3 mimetic ABT-737 targets the apoptotic machinery in acute lymphoblastic leukemia resulting in synergistic in vitro and in vivo interactions with established drugs. Mol Pharmacol. 2010;77(3):483–94.PubMedCrossRef
102.
Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci U S A. 2012;109(8):2766–71.PubMedCrossRef
103.
Song JH, Kandasamy K, Zemskova M, Lin YW, Kraft AS. The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res. 2011;71(2):506–15.PubMedCrossRef
104.
Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007;67(2):782–91.PubMedCrossRef
105.
Boiani M, Daniel C, Liu X, Hogarty MD, Marnett LJ. The stress protein BAG3 stabilizes Mcl-1 protein and promotes survival of cancer cells and resistance to antagonist ABT-737. J Biol Chem. 2013;288(10):6980–90.PubMedPubMedCentralCrossRef
106.
Zhang C, Li YL, Weng X, Li LY, Zhou MX, Zhang DY, et al. Nedaplatin enhanced apoptotic effects of ABT-737 in human cancer cells via Mcl-1 inhibition. Oncol Lett. 2016;12(5):4195–202.PubMedPubMedCentralCrossRef
107.
108.
Allaman-Pillet N, Oberson A, Munier F, Schorderet DF. The Bcl-2/Bcl-XL inhibitor ABT-737 promotes death of retinoblastoma cancer cells. Ophthalmic Genet. 2013;34(1–2):1–13.PubMedCrossRef
109.
Reuland SN, Goldstein NB, Partyka KA, Smith S, Luo Y, Fujita M, et al. ABT-737 synergizes with Bortezomib to kill melanoma cells. Biol Open. 2012;1(2):92–100.PubMedCrossRef
110.
Yin S, Dong Y, Li J, Fan L, Wang L, Lu J, et al. Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and bad. Apoptosis. 2012;17(4):388–99.PubMedCrossRef
111.
Zhang S, Li G, Ma X, Wang Y, Liu G, Feng L, et al. Norcantharidin enhances ABT-737-induced apoptosis in hepatocellular carcinoma cells by transcriptional repression of Mcl-1. Cell Signal. 2012;24(9):1803–9.PubMedCrossRef
112.
Bogenberger JM, Delman D, Hansen N, Valdez R, Fauble V, Mesa RA, et al. Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma. 2015;56(1):226–9.PubMedCrossRef
113.
Li JY, Li YY, Jin W, Yang Q, Shao ZM, Tian XS. ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL. J Exp Clin Cancer Res. 2012;31:102.PubMedPubMedCentralCrossRef
114.
Chen ZJ, Zhang B, Pan SH, Zhao HM, Zhang Y. Feng WH et al: [Bcl-2 inhibitor ABT-737 enhances the cisplatin-induced apoptosis in breast cancer T47D cells]. Zhonghua Zhong Liu Za Zhi. 2011;33(12):891–5.PubMed
115.
Choi JE, Woo SM, Min KJ, Kang SH, Lee SJ, Kwon TK. Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells. Oncol Rep. 2015;33(3):1395–401.PubMedCrossRef
116.
Hwang E, Hwang SH, Kim J, Park JH, Oh S, Kim YA, et al. ABT-737 ameliorates docetaxel resistance in triple negative breast cancer cell line. Ann Surg Treat Res. 2018;95(5):240–8.PubMedPubMedCentralCrossRef
117.
Raats DA, de Bruijn MT, Steller EJ, Emmink BL, Borel-Rinkes IH, Kranenburg O. Synergistic killing of colorectal cancer cells by oxaliplatin and ABT-737. Cell Oncol (Dordr). 2011;34(4):307–13.CrossRef
118.
Huang S, Sinicrope FA. Celecoxib-induced apoptosis is enhanced by ABT-737 and by inhibition of autophagy in human colorectal cancer cells. Autophagy. 2010;6(2):256–69.PubMedCrossRef
119.
Premkumar DR, Jane EP, DiDomenico JD, Vukmer NA, Agostino NR, Pollack IF. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines. J Pharmacol Exp Ther. 2012;341(3):859–72.PubMedPubMedCentralCrossRef
120.
Li R, Zang Y, Li C, Patel NS, Grandis JR, Johnson DE. ABT-737 synergizes with chemotherapy to kill head and neck squamous cell carcinoma cells via a Noxa-mediated pathway. Mol Pharmacol. 2009;75(5):1231–9.PubMedPubMedCentralCrossRef
121.
Shen J, Xu L, Zhao Q. Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo. Biochem Biophys Res Commun. 2016;473(4):1170–6.PubMedCrossRef
122.
Opydo-Chanek M, Rak A, Cierniak A, Mazur L. Combination of ABT-737 and resveratrol enhances DNA damage and apoptosis in human T-cell acute lymphoblastic leukemia MOLT-4 cells. Toxicol in Vitro. 2017;42:38–46.PubMedCrossRef
123.
Opydo-Chanek M, Mazur L. Comparison of in vitro antileukemic activity of obatoclax and ABT-737. Tumour Biol. 2016;37(8):10839–49.PubMedCrossRef
124.
Ugarenko M, Nudelman A, Rephaeli A, Kimura K, Phillips DR, Cutts SM. ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. Biochem Pharmacol. 2010;79(3):339–49.PubMedCrossRef
125.
Zheng R, You Z, Jia J, Lin S, Han S, Liu A, et al. Curcumin enhances the antitumor effect of ABT-737 via activation of the ROS-ASK1-JNK pathway in hepatocellular carcinoma cells. Mol Med Rep. 2016;13(2):1570–6.PubMedCrossRef
126.
Kim EY, Jung JY, Kim A, Chang YS, Kim SK. ABT-737 synergizes with cisplatin bypassing aberration of apoptotic pathway in non-small cell lung Cancer. Neoplasia. 2017;19(4):354–63.PubMedPubMedCentralCrossRef
127.
Kim LH, Shin JA, Jang B, Yang IH, Won DH, Jeong JH, et al. Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells. Arch Oral Biol. 2017;73:1–6.PubMedCrossRef
128.
Zhang F, Yu X, Liu X, Zhou T, Nie T, Cheng M, et al. ABT-737 potentiates cisplatin-induced apoptosis in human osteosarcoma cells via the mitochondrial apoptotic pathway. Oncol Rep. 2017;38(4):2301–8.PubMedCrossRef
129.
Li YL, Sun J, Hu X, Pan YN, Yan W, Li QY, et al. Epothilone B induces apoptosis and enhances apoptotic effects of ABT-737 on human cancer cells via PI3K/AKT/mTOR pathway. J Cancer Res Clin Oncol. 2016;142(11):2281–9.PubMedCrossRef
130.
Florent R, Weiswald LB, Lambert B, Brotin E, Abeilard E, Louis MH, et al. Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib. Cell Death Dis. 2020;11(5):380.PubMedPubMedCentralCrossRef
131.
De Wolf E, De Wolf C, Richardson A. ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells. Oncol Lett. 2018;15(2):1979–84.PubMed
132.
Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, et al. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007;13(23):7191–8.PubMedCrossRef
133.
Jain HV, Meyer-Hermann M. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas. Cancer Res. 2011;71(3):705–15.PubMedCrossRef
134.
Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008;283(36):25003–13.PubMedPubMedCentralCrossRef
135.
Broecker-Preuss M, Becher-Boveleth N, Muller S, Mann K. The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells. Cancer Cell Int. 2016;16:27.PubMedPubMedCentralCrossRef
136.
Shen HP, Wu WJ, Ko JL, Wu TF, Yang SF, Wu CH, et al. Effects of ABT-737 combined with irradiation treatment on uterine cervical cancer cells. Oncol Lett. 2019;18(4):4328–36.PubMedPubMedCentral
137.
138.
Vogler M, Furdas SD, Jung M, Kuwana T, Dyer MJ, Cohen GM. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood. Clin Cancer Res. 2010;16(16):4217–25.PubMedPubMedCentralCrossRef
139.
Lian BSX, Yek AEH, Shuvas H, Abdul Rahman SF, Muniandy K, Mohana-Kumaran N. Synergistic anti-proliferative effects of combination of ABT-263 and MCL-1 selective inhibitor A-1210477 on cervical cancer cell lines. BMC Res Notes. 2018;11(1):197.PubMedPubMedCentralCrossRef
140.
Ackler S, Mitten MJ, Foster K, Oleksijew A, Refici M, Tahir SK, et al. The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol. 2010;66(5):869–80.PubMedCrossRef
141.
Kivioja JL, Thanasopoulou A, Kumar A, Kontro M, Yadav B, Majumder MM, et al. Dasatinib and navitoclax act synergistically to target NUP98-NSD1(+)/FLT3-ITD(+) acute myeloid leukemia. Leukemia. 2019;33(6):1360–72.PubMedCrossRef
142.
Polier G, Giaisi M, Kohler R, Muller WW, Lutz C, Buss EC, et al. Targeting CDK9 by wogonin and related natural flavones potentiates the anti-cancer efficacy of the Bcl-2 family inhibitor ABT-263. Int J Cancer. 2015;136(3):688–98.PubMed
143.
Shao H, Jing K, Mahmoud E, Huang H, Fang X, Yu C. Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263. Mol Cancer Ther. 2013;12(12):2640–50.PubMedCrossRef
144.
Li J, Chen Y, Wan J, Liu X, Yu C, Li W. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells. Br J Pharmacol. 2014;171(13):3182–95.PubMedPubMedCentralCrossRef
145.
Sale MJ, Cook SJ. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Biochem J. 2013;450(2):285–94.PubMedCrossRef
146.
Chen Q, Song S, Wei S, Liu B, Honjo S, Scott A, et al. ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer. Oncotarget. 2015;6(28):25883–96.PubMedPubMedCentralCrossRef
147.
Lin QH, Que FC, Gu CP, Zhong DS, Zhou D, Kong Y, et al. ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro. Acta Pharmacol Sin. 2017;38(12):1632–41.PubMedPubMedCentralCrossRef
148.
Britt EL, Raman S, Leek K, Sheehy CH, Kim SW, Harada H. Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment. PLoS One. 2019;14(7):e0219398.PubMedPubMedCentralCrossRef
149.
Wang G, Zhan Y, Wang H, Li W. ABT-263 sensitizes TRAIL-resistant hepatocarcinoma cells by downregulating the Bcl-2 family of anti-apoptotic protein. Cancer Chemother Pharmacol. 2012;69(3):799–805.PubMedCrossRef
150.
Sakuma Y, Tsunezumi J, Nakamura Y, Yoshihara M, Matsukuma S, Koizume S, et al. ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. Oncol Rep. 2011;25(3):661–7.PubMedCrossRef
151.
Matsumoto M, Nakajima W, Seike M, Gemma A, Tanaka N. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells. Biochem Biophys Res Commun. 2016;473(2):490–6.PubMedCrossRef
152.
Nakajima W, Sharma K, Hicks MA, Le N, Brown R, Krystal GW, et al. Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer. Cancer Biol Ther. 2016;17(1):27–35.PubMedCrossRef
153.
Ackler S, Xiao Y, Mitten MJ, Foster K, Oleksijew A, Refici M, et al. ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther. 2008;7(10):3265–74.PubMedCrossRef
154.
Wang X, Gu Z, Li G, Zhang S, Cao Z, Yang Z, et al. Norcantharidin enhances ABT-263-mediated anticancer activity in neuroblastoma cells by upregulation of Noxa. Oncol Rep. 2014;32(2):716–22.PubMedCrossRef
155.
Wang C, Huang SB, Yang MC, Lin YT, Chu IH, Shen YN, et al. Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells. PLoS One. 2015;10(3):e0120913.PubMedPubMedCentralCrossRef
156.
Wei X, Zhou P, Lin X, Lin Y, Wu S, Diao P, et al. MLN2238 synergizes BH3 mimetic ABT-263 in castration-resistant prostate cancer cells by induction of NOXA. Tumour Biol. 2014;35(10):10213–21.PubMedCrossRef
157.
Wong M, Tan N, Zha J, Peale FV, Yue P, Fairbrother WJ, et al. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol Cancer Ther. 2012;11(4):1026–35.PubMedCrossRef
158.
Li X, Li B, Ni Z, Zhou P, Wang B, He J, et al. Metformin synergizes with BCL-XL/BCL-2 inhibitor ABT-263 to induce apoptosis specifically in p53-defective Cancer cells. Mol Cancer Ther. 2017;16(9):1806–18.PubMedCrossRef
159.
Wang B, Ni Z, Dai X, Qin L, Li X, Xu L, et al. The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells. Mol Cancer. 2014;13:98.PubMedPubMedCentralCrossRef
160.
Lee EY, Gong EY, Shin JS, Moon JH, Shim HJ, Kim SM, et al. Human breast cancer cells display different sensitivities to ABT-263 based on the level of survivin. Toxicol in Vitro. 2018;46:229–36.PubMedCrossRef
161.
Lee YC, Wang LJ, Huang CH, Chiou JT, Shi YJ, Chang LS. Inhibition of EGFR pathway promotes the cytotoxicity of ABT-263 in human leukemia K562 cells by blocking MCL1 upregulation. Biochem Pharmacol. 2020;178:114047.PubMedCrossRef
162.
Xu J, Zhu GY, Cao D, Pan H, Li YW. Gossypol overcomes EGFR-TKIs resistance in non-small cell lung cancer cells by targeting YAP/TAZ and EGFR(L858R/T790M). Biomed Pharmacother. 2019;115:108860.PubMedCrossRef
163.
Wang Y, Lai H, Fan X, Luo L, Duan F, Jiang Z, et al. Gossypol inhibits non-small cell lung Cancer cells proliferation by targeting EGFR(L858R/T790M). Front Pharmacol. 2018;9:728.PubMedPubMedCentralCrossRef
164.
Huang YW, Wang LS, Chang HL, Ye W, Dowd MK, Wan PJ, et al. Molecular mechanisms of (−)-gossypol-induced apoptosis in human prostate cancer cells. Anticancer Res. 2006;26(3A):1925–33.PubMed
165.
Zhang M, Liu H, Tian Z, Griffith BN, Ji M, Li QQ. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways. Life Sci. 2007;80(8):767–74.PubMedCrossRef
166.
Wang J, Jin L, Li X, Deng H, Chen Y, Lian Q, et al. Gossypol induces apoptosis in ovarian cancer cells through oxidative stress. Mol BioSyst. 2013;9(6):1489–97.PubMedCrossRef
167.
Macoska JA, Adsule S, Tantivejkul K, Wang S, Pienta KJ, Lee CT. (−)gossypol promotes the apoptosis of bladder cancer cells in vitro. Pharmacol Res. 2008;58(5–6):323–31.PubMedCrossRef
168.
Gilbert NE, O'Reilly JE, Chang CJ, Lin YC, Brueggemeier RW. Antiproliferative activity of gossypol and gossypolone on human breast cancer cells. Life Sci. 1995;57(1):61–7.PubMedCrossRef
169.
Ye W, Chang HL, Wang LS, Huang YW, Shu S, Sugimoto Y, et al. Induction of apoptosis by (−)-gossypol-enriched cottonseed oil in human breast cancer cells. Int J Mol Med. 2010;26(1):113–9.PubMed
170.
Meng Y, Tang W, Dai Y, Wu X, Liu M, Ji Q, et al. Natural BH3 mimetic (−)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa. Mol Cancer Ther. 2008;7(7):2192–202.PubMedPubMedCentralCrossRef
171.
Volate SR, Kawasaki BT, Hurt EM, Milner JA, Kim YS, White J, et al. Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Mol Cancer Ther. 2010;9(2):461–70.PubMedPubMedCentralCrossRef
172.
Zhang G, Wang Z, Chen W, Cao Y, Wu J, Qiang G, et al. Dual effects of gossypol on human hepatocellular carcinoma via endoplasmic reticulum stress and autophagy. Int J Biochem Cell Biol. 2019;113:48–57.PubMedCrossRef
173.
174.
Lian J, Ni Z, Dai X, Su C, Smith AR, Xu L, et al. Sorafenib sensitizes (−)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation. Mol Cancer Ther. 2012;11(2):416–26.PubMedCrossRef
175.
Jang GH, Lee M. BH3-mimetic gossypol-induced autophagic cell death in mutant BRAF melanoma cells with high expression of p21Cip(1). Life Sci. 2014;102(1):41–8.PubMedCrossRef
176.
Huang YW, Wang LS, Dowd MK, Wan PJ. Lin YC: (−)-gossypol reduces invasiveness in metastatic prostate cancer cells. Anticancer Res. 2009;29(6):2179–88.PubMed
177.
Meyer N, Zielke S, Michaelis JB, Linder B, Warnsmann V, Rakel S, et al. AT 101 induces early mitochondrial dysfunction and HMOX1 (heme oxygenase 1) to trigger mitophagic cell death in glioma cells. Autophagy. 2018;14(10):1693–709.PubMedPubMedCentralCrossRef
178.
Etxebarria A, Landeta O, Antonsson B, Basanez G. Regulation of antiapoptotic MCL-1 function by gossypol: mechanistic insights from in vitro reconstituted systems. Biochem Pharmacol. 2008;76(11):1563–76.PubMedCrossRef
179.
Mallick DJ, Eastman A. AT101 [(−)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA. Cancers (Basel). 2020;12(8):2298.CrossRef
180.
Kim HY, Lee BI, Jeon JH, Kim DK, Kang SG, Shim JK, et al. Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres. Biomolecules. 2019;9(10):595.PubMedCentralCrossRef
181.
Meng Y, Li Y, Li J, Li H, Fu J. Liu Y et al: (−)gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells. Leuk Lymphoma. 2007;48(11):2204–12.PubMedCrossRef
182.
Yang D, Qu J, Qu X, Cao Y, Xu L, Hou K, et al. Gossypol sensitizes the antitumor activity of 5-FU through down-regulation of thymidylate synthase in human colon carcinoma cells. Cancer Chemother Pharmacol. 2015;76(3):575–86.PubMedCrossRef
183.
Wong FY, Liem N, Xie C, Yan FL, Wong WC, Wang L, et al. Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression. PLoS One. 2012;7(12):e50786.PubMedPubMedCentralCrossRef
184.
Atmaca H, Gorumlu G, Karaca B, Degirmenci M, Tunali D, Cirak Y, et al. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. Eur Cytokine Netw. 2009;20(3):121–30.PubMedCrossRef
185.
Yeow WS, Baras A, Chua A, Nguyen DM, Sehgal SS, Schrump DS, et al. Gossypol, a phytochemical with BH3-mimetic property, sensitizes cultured thoracic cancer cells to Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Thorac Cardiovasc Surg. 2006;132(6):1356–62.PubMedCrossRef
186.
Bulut G, Atmaca H, Karaca B. Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells. Future Oncol. 2020;16(3):4485–95.PubMedCrossRef
187.
Mohammad RM, Wang S, Banerjee S, Wu X, Chen J, Sarkar FH. Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, (−)-gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line. Pancreas. 2005;31(4):317–24.PubMedCrossRef
188.
Xu L, Yang D, Wang S, Tang W, Liu M. Davis M et al: (−)-gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. Mol Cancer Ther. 2005;4(2):197–205.PubMedCrossRef
189.
McGregor N, Patel L, Craig M, Weidner S, Wang S, Pienta KJ. AT-101 (R-(−)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model. J Cell Biochem. 2010;110(5):1187–94.PubMedCrossRef
190.
Konopleva M, Watt J, Contractor R, Tsao T, Harris D, Estrov Z, et al. Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008;68(9):3413–20.PubMedPubMedCentralCrossRef
191.
192.
193.
Li J, Viallet J, Haura EB. A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells. Cancer Chemother Pharmacol. 2008;61(3):525–34.PubMedCrossRef
194.
Champa D, Russo MA, Liao XH, Refetoff S, Ghossein RA, Di Cristofano A. Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. Endocr Relat Cancer. 2014;21(5):755–67.PubMedPubMedCentralCrossRef
195.
Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Blood. 2012;119(25):6089–98.PubMedPubMedCentralCrossRef
196.
Jimenez-Guerrero R, Gasca J, Flores ML, Perez-Valderrama B, Tejera-Parrado C, Medina R, et al. Obatoclax and paclitaxel synergistically induce apoptosis and overcome paclitaxel resistance in urothelial cancer cells. Cancers (Basel). 2018;10(12):490.CrossRef
197.
Steele TM, Talbott GC, Sam A, Tepper CG, Ghosh PM, Vinall RL. Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators. Int J Mol Sci. 2019;20(6):1285–300.PubMedCentralCrossRef
198.
Mott JL, Bronk SF, Mesa RA, Kaufmann SH, Gores GJ. BH3-only protein mimetic obatoclax sensitizes cholangiocarcinoma cells to Apo2L/TRAIL-induced apoptosis. Mol Cancer Ther. 2008;7(8):2339–47.PubMedPubMedCentralCrossRef
199.
Gariboldi MB, Taiana E, Bonzi MC, Craparotta I, Giovannardi S, Mancini M, et al. The BH3-mimetic obatoclax reduces HIF-1alpha levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil. Cancer Lett. 2015;364(2):156–64.PubMedCrossRef
200.
Zhao XY, Lin QH, Que FC, Gu CP, Yu L. Liu SW: [synergistic anti-tumor effect of obatoclax and MG-132 in esophageal cancer cell line CaES-17]. Nan Fang Yi Ke Da Xue Xue Bao. 2016;36(4):506–13.PubMed
201.
Berghauser Pont LM, Spoor JK, Venkatesan S, Swagemakers S, Kloezeman JJ, Dirven CM, et al. The Bcl-2 inhibitor Obatoclax overcomes resistance to histone deacetylase inhibitors SAHA and LBH589 as radiosensitizers in patient-derived glioblastoma stem-like cells. Genes Cancer. 2014;5(11–12):445–59.PubMedPubMedCentralCrossRef
202.
Yin YP, Shi WH, Deng K, Liu XL, Li H, Lv XT, et al. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer. Acta Pharmacol Sin. 2021;42(8):1298–310.PubMedCrossRef
203.
Crawford N, Chacko AD, Savage KI, McCoy F, Redmond K, Longley DB, et al. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Apoptosis. 2011;16(3):311–20.PubMedCrossRef
204.
Cournoyer S, Addioui A, Belounis A, Beaunoyer M, Nyalendo C, Le Gall R, et al. GX15-070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma. BMC Cancer. 2019;19(1):1018.PubMedPubMedCentralCrossRef
205.
Hou XF, Li S, Wu C, Li K, Xu SN, Wang JF. Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions. Mol Med Rep. 2018;18(1):495–501.PubMed
206.
Huang S, Okumura K, Sinicrope FA. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells. Clin Cancer Res. 2009;15(1):150–9.PubMedPubMedCentralCrossRef
207.
Wang G, Chen S, Edwards H, Cui X, Cui L, Ge Y. Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells. Oncol Rep. 2014;32(6):2789–94.PubMedCrossRef
208.
Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, et al. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett. 2014;348(1–2):20–8.PubMedCrossRef
209.
Wei WJ, Sun ZK, Shen CT, Song HJ, Zhang XY, Qiu ZL, et al. Obatoclax and LY3009120 efficiently overcome Vemurafenib resistance in differentiated thyroid cancer. Theranostics. 2017;7(4):987–1001.PubMedPubMedCentralCrossRef
210.
Hauck P, Chao BH, Litz J, Krystal GW. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737. Mol Cancer Ther. 2009;8(4):883–92.PubMedCrossRef
211.
Nakajima W, Hicks MA, Tanaka N, Krystal GW, Harada H. Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer. Cell Death Dis. 2014;5:e1052.PubMedPubMedCentralCrossRef
212.
Sakakibara-Konishi J, Oizumi S, Kikuchi J, Kikuchi E, Mizugaki H, Kinoshita I, et al. Expression of Bim, Noxa, and Puma in non-small cell lung cancer. BMC Cancer. 2012;12:286.PubMedPubMedCentralCrossRef
213.
Yan J, Zhong N, Liu G, Chen K, Liu X, Su L, et al. Usp9x- and Noxa-mediated Mcl-1 downregulation contributes to pemetrexed-induced apoptosis in human non-small-cell lung cancer cells. Cell Death Dis. 2014;5:e1316.PubMedPubMedCentralCrossRef
214.
Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood. 2007;109(4):1660–8.PubMedCrossRef
215.
Zhang LN, Li JY, Xu W. A review of the role of Puma, Noxa and Bim in the tumorigenesis, therapy and drug resistance of chronic lymphocytic leukemia. Cancer Gene Ther. 2013;20(1):1–7.PubMedCrossRef
216.
Marshall AD, Picchione F, Geltink RI, Grosveld GC. PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis. Neoplasia. 2013;15(7):738–48.PubMedPubMedCentralCrossRef
217.
Ramirez-Peinado S, Alcazar-Limones F, Lagares-Tena L, El Mjiyad N, Caro-Maldonado A, Tirado OM, et al. 2-deoxyglucose induces Noxa-dependent apoptosis in alveolar rhabdomyosarcoma. Cancer Res. 2011;71(21):6796–806.PubMedCrossRef
218.
Diallo JS, Aldejmah A, Mouhim AF, Peant B, Fahmy MA, Koumakpayi IH, et al. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res. 2007;13(23):7044–52.PubMedCrossRef
219.
Lin C, Zhao XY, Li L, Liu HY, Cao K, Wan Y, et al. NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to cisplatin. PLoS One. 2012;7(5):e36722.PubMedPubMedCentralCrossRef
220.
Conti A, Majorini MT, Elliott R, Ashworth A, Lord CJ, Cancelliere C, et al. Oncogenic KRAS sensitizes premalignant, but not malignant cells, to Noxa-dependent apoptosis through the activation of the MEK/ERK pathway. Oncotarget. 2015;6(13):10994–1008.PubMedPubMedCentralCrossRef
221.
Jansson AK, Emterling AM, Arbman G, Sun XF. Noxa in colorectal cancer: a study on DNA, mRNA and protein expression. Oncogene. 2003;22(30):4675–8.PubMedCrossRef
222.
Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, et al. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017;8(29):46801–17.PubMedCrossRef
223.
Kelly KR, Espitia CM, Mahalingam D, Oyajobi BO, Coffey M, Giles FJ, et al. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma. Oncogene. 2012;31(25):3023–38.PubMedCrossRef
224.
Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393–403.PubMedCrossRef
225.
Chen LS, Balakrishnan K, Gandhi V. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol. 2010;80(12):1936–45.PubMedPubMedCentralCrossRef
226.
Erlacher M, Labi V, Manzl C, Bock G, Tzankov A, Hacker G, et al. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med. 2006;203(13):2939–51.PubMedPubMedCentralCrossRef
227.
Edwards AL, Gavathiotis E, LaBelle JL, Braun CR, Opoku-Nsiah KA, Bird GH, et al. Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem Biol. 2013;20(7):888–902.PubMedPubMedCentralCrossRef
228.
Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell. 2002;2(3):183–92.PubMedCrossRef
229.
Day CL, Smits C, Fan FC, Lee EF, Fairlie WD, Hinds MG. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J Mol Biol. 2008;380(5):958–71.PubMedCrossRef
230.
Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov. 2012;11(2):109–24.PubMedCrossRef
231.
Condon SM, Mitsuuchi Y, Deng Y, LaPorte MG, Rippin SR, Haimowitz T, et al. Birinapant, a smac-mimetic with improved tolerability for the treatment of solid tumors and hematological malignancies. J Med Chem. 2014;57(9):3666–77.PubMedCrossRef
232.
Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125(7):1253–67.PubMedPubMedCentralCrossRef
233.
de Almagro MC, Vucic D. The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Exp Oncol. 2012;34(3):200–11.PubMed
234.
Obexer P, Ausserlechner MJ. X-linked inhibitor of apoptosis protein - a critical death resistance regulator and therapeutic target for personalized cancer therapy. Front Oncol. 2014;4:197.PubMedPubMedCentralCrossRef
235.
Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 2007;131(4):669–81.PubMedCrossRef
236.
Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J, et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell. 2008;30(6):689–700.PubMedCrossRef
237.
Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E, et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci U S A. 2008;105(33):11778–83.PubMedPubMedCentralCrossRef
238.
Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU, et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell. 2007;131(4):682–93.PubMedCrossRef
239.
Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002;8(8):808–15.PubMedCrossRef
240.
Carter BZ, Milella M, Tsao T, McQueen T, Schober WD, Hu W, et al. Regulation and targeting of antiapoptotic XIAP in acute myeloid leukemia. Leukemia. 2003;17(11):2081–9.PubMedCrossRef
241.
Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH. Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and cIAP1 in situ. J Biol Chem. 2002;277(46):44236–43.PubMedCrossRef
242.
Silke J, Hawkins CJ, Ekert PG, Chew J, Day CL, Pakusch M, et al. The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3- and caspase 9-interacting sites. J Cell Biol. 2002;157(1):115–24.PubMedPubMedCentralCrossRef
243.
Bratton SB, Walker G, Srinivasula SM, Sun XM, Butterworth M, Alnemri ES, et al. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J. 2001;20(5):998–1009.PubMedPubMedCentralCrossRef
244.
Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, et al. Structural basis of IAP recognition by Smac/DIABLO. Nature. 2000;408(6815):1008–12.PubMedCrossRef
245.
Ekert PG, Silke J, Hawkins CJ, Verhagen AM, Vaux DL. DIABLO promotes apoptosis by removing MIHA/XIAP from processed caspase 9. J Cell Biol. 2001;152(3):483–90.PubMedPubMedCentralCrossRef
246.
Eckhardt I, Roesler S, Fulda S. Identification of DR5 as a critical, NF-kappaB-regulated mediator of Smac-induced apoptosis. Cell Death Dis. 2013;4:e936.PubMedPubMedCentralCrossRef
247.
248.
Wagner L, Marschall V, Karl S, Cristofanon S, Zobel K, Deshayes K, et al. Smac mimetic sensitizes glioblastoma cells to Temozolomide-induced apoptosis in a RIP1- and NF-kappaB-dependent manner. Oncogene. 2013;32(8):988–97.PubMedCrossRef
249.
Chromik J, Safferthal C, Serve H, Fulda S. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis. Cancer Lett. 2014;344(1):101–9.PubMedCrossRef
250.
Belz K, Schoeneberger H, Wehner S, Weigert A, Bonig H, Klingebiel T, et al. Smac mimetic and glucocorticoids synergize to induce apoptosis in childhood ALL by promoting ripoptosome assembly. Blood. 2014;124(2):240–50.PubMedCrossRef
251.
Probst BL, Liu L, Ramesh V, Li L, Sun H, Minna JD, et al. Smac mimetics increase cancer cell response to chemotherapeutics in a TNF-alpha-dependent manner. Cell Death Differ. 2010;17(10):1645–54.PubMedCrossRef
252.
Wang L, Du F, Wang X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell. 2008;133(4):693–703.PubMedCrossRef
253.
Chen Z, Chen J, Liu H, Dong W, Huang X, Yang D, et al. The SMAC mimetic APG-1387 sensitizes immune-mediated cell apoptosis in hepatocellular carcinoma. Front Pharmacol. 2018;9:1298.PubMedPubMedCentralCrossRef
254.
Li BX, Wang HB, Qiu MZ, Luo QY, Yi HJ, Yan XL, et al. Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway. J Exp Clin Cancer Res. 2018;37(1):53.PubMedPubMedCentralCrossRef
255.
Kamata E, Kawamoto T, Ueha T, Hara H, Fukase N, Minoda M, et al. Synergistic effects of a Smac mimetic with doxorubicin against human osteosarcoma. Anticancer Res. 2017;37(11):6097–106.PubMed
256.
Lee EK, Jinesh GG, Laing NM, Choi W, McConkey DJ, Kamat AM. A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biol Ther. 2013;14(9):812–22.PubMedPubMedCentralCrossRef
257.
Brumatti G, Ma C, Lalaoui N, Nguyen NY, Navarro M, Tanzer MC, et al. The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia. Sci Transl Med. 2016;8(339):339ra369.CrossRef
258.
Eytan DF, Snow GE, Carlson S, Derakhshan A, Saleh A, Schiltz S, et al. SMAC mimetic Birinapant plus radiation eradicates human head and neck cancers with genomic amplifications of cell death genes FADD and BIRC2. Cancer Res. 2016;76(18):5442–54.PubMedPubMedCentralCrossRef
259.
Colombo M, Marabese M, Vargiu G, Broggini M, Caiola E. Activity of Birinapant, a SMAC mimetic compound, Alone or in Combination in NSCLCs With Different Mutations. Front Oncol. 2020;10:532292.PubMedPubMedCentralCrossRef
260.
Noonan AM, Cousins A, Anderson D, Zeligs KP, Bunch K, Hernandez L, et al. Matrix drug screen identifies synergistic drug combinations to augment smac mimetic activity in ovarian cancer. Cancers (Basel). 2020;12(12):3784.CrossRef
261.
Hernandez LF, Dull AB, Korrapati S, Annunziata CM. Smac-mimetic enhances antitumor effect of standard chemotherapy in ovarian cancer models via caspase 8-independent mechanism. Cell Death Discov. 2021;7(1):134.PubMedPubMedCentralCrossRef
262.
Lueck SC, Russ AC, Botzenhardt U, Schlenk RF, Zobel K, Deshayes K, et al. Smac mimetic induces cell death in a large proportion of primary acute myeloid leukemia samples, which correlates with defined molecular markers. Oncotarget. 2016;7(31):49539–51.PubMedPubMedCentralCrossRef
263.
Seyfrid M, Marschall V, Fulda S. Reactive oxygen species contribute toward Smac mimetic/temozolomide-induced cell death in glioblastoma cells. Anti-Cancer Drugs. 2016;27(10):953–9.PubMedCrossRef
264.
Hehlgans S, Oppermann J, Reichert S, Fulda S, Rodel C, Rodel F. The SMAC mimetic BV6 sensitizes colorectal cancer cells to ionizing radiation by interfering with DNA repair processes and enhancing apoptosis. Radiat Oncol. 2015;10:198.PubMedPubMedCentralCrossRef
265.
Marschall V, Fulda S. Smac mimetic-induced upregulation of interferon-beta sensitizes glioblastoma to temozolomide-induced cell death. Cell Death Dis. 2015;6:e1888.PubMedPubMedCentralCrossRef
266.
El-Mesery M, Shaker ME, Elgaml A. The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-alpha and TRAIL-induced apoptosis. Exp Biol Med (Maywood). 2016;241(18):2015–22.CrossRef
267.
Reiter M, Eckhardt I, Haferkamp A, Fulda S. Smac mimetic sensitizes renal cell carcinoma cells to interferon-alpha-induced apoptosis. Cancer Lett. 2016;375(1):1–8.PubMedCrossRef
268.
Huerta S, Gao X, Livingston EH, Kapur P, Sun H, Anthony T. In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201. Surgery. 2010;148(2):346–53.PubMedCrossRef
269.
Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, et al. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 2010;70(7):2852–61.PubMedPubMedCentralCrossRef
270.
Runckel K, Barth MJ, Mavis C, Gu JJ, Hernandez-Ilizaliturri FJ. The SMAC mimetic LCL-161 displays antitumor activity in preclinical models of rituximab-resistant B-cell lymphoma. Blood Adv. 2018;2(23):3516–25.PubMedPubMedCentralCrossRef
271.
Chang YC, Kondapuram SK, Yang TH, Syed SB, Cheng SM, Lin TY, et al. The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells. Toxicol Appl Pharmacol. 2020;401:115080.PubMedCrossRef
272.
Yang L, Kumar B, Shen C, Zhao S, Blakaj D, Li T, et al. LCL161, a SMAC-mimetic, preferentially Radiosensitizes human papillomavirus-negative head and neck squamous cell carcinoma. Mol Cancer Ther. 2019;18(6):1025–35.PubMedPubMedCentralCrossRef
273.
Brands RC, Herbst F, Hartmann S, Seher A, Linz C, Kubler AC, et al. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines. Clin Oral Investig. 2016;20(9):2325–32.PubMedCrossRef
274.
Yang D, Zhao Y, Li AY, Wang S, Wang G, Sun Y. Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis. Breast Cancer Res Treat. 2012;133(1):189–99.PubMedCrossRef
275.
Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S, et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther. 2011;10(5):902–14.PubMedPubMedCentralCrossRef
276.
Zhou B, Zhang J, Chen G, You L, Zhang TP, Zhao YP. Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer. Cancer Lett. 2013;329(1):118–24.PubMedCrossRef
277.
Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther. 2010;10(9):885–92.PubMedPubMedCentralCrossRef
278.
Yang C, Ran Q, Zhou Y, Liu S, Zhao C, Yu X, et al. Doxorubicin sensitizes cancer cells to Smac mimetic via synergistic activation of the CYLD/RIPK1/FADD/caspase-8-dependent apoptosis. Apoptosis. 2020;25(5–6):441–55.PubMedCrossRef
279.
Tao Z, McCall NS, Wiedemann N, Vuagniaux G, Yuan Z, Lu B. SMAC mimetic Debio 1143 and ablative radiation therapy synergize to enhance antitumor immunity against lung Cancer. Clin Cancer Res. 2019;25(3):1113–24.PubMedCrossRef
280.
Dai Y, Liu M, Tang W, Li Y, Lian J, Lawrence TS, et al. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB. BMC Cancer. 2009;9:392.PubMedPubMedCentralCrossRef
281.
Hashim YM, Vangveravong S, Sankpal NV, Binder PS, Liu J, Goedegebuure SP, et al. The targeted SMAC mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer. J Exp Clin Cancer Res. 2017;36(1):14.PubMedPubMedCentralCrossRef
282.
Loeder S, Zenz T, Schnaiter A, Mertens D, Winkler D, Dohner H, et al. A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia. Cancer Res. 2009;69(23):8977–86.PubMedCrossRef
283.
Fakler M, Loeder S, Vogler M, Schneider K, Jeremias I, Debatin KM, et al. Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance. Blood. 2009;113(8):1710–22.PubMedCrossRef
284.
Fingas CD, Blechacz BR, Smoot RL, Guicciardi ME, Mott J, Bronk SF, et al. A smac mimetic reduces TNF related apoptosis inducing ligand (TRAIL)-induced invasion and metastasis of cholangiocarcinoma cells. Hepatology. 2010;52(2):550–61.PubMedCrossRef
285.
Vellanki SH, Grabrucker A, Liebau S, Proepper C, Eramo A, Braun V, et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia. 2009;11(8):743–52.PubMedPubMedCentralCrossRef
286.
Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis. 2013;4:e802.PubMedPubMedCentralCrossRef
287.
Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst. 2014;106(2):djt440.PubMedPubMedCentralCrossRef
288.
Weisberg E, Kung AL, Wright RD, Moreno D, Catley L, Ray A, et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. Mol Cancer Ther. 2007;6(7):1951–61.PubMedCrossRef
289.
Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ, et al. Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Res. 2009;11(3):R41.PubMedPubMedCentralCrossRef
290.
Hao Q, Tang H. Interferon-gamma and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNFalpha-independent manner. Cancer Cell Int. 2018;18:84.PubMedPubMedCentralCrossRef
291.
Ding J, Qin D, Zhang Y, Li Q, Li Y, Li J. SMAC mimetic birinapant inhibits hepatocellular carcinoma growth by activating the cIAP1/TRAF3 signaling pathway. Mol Med Rep. 2020;21(3):1251–7.PubMedPubMedCentral
292.
Lalaoui N, Merino D, Giner G, Vaillant F, Chau D, Liu L, et al. Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death Differ. 2020;27(10):2768–80.PubMedPubMedCentralCrossRef
293.
Wang Y, Wang Y, Fan X, Song J, Wu H, Han J, et al. ABT-199-mediated inhibition of Bcl-2 as a potential therapeutic strategy for nasopharyngeal carcinoma. Biochem Biophys Res Commun. 2018;503(3):1214–20.PubMedCrossRef
294.
Diaz-Flores E, Comeaux EQ, Kim KL, Melnik E, Beckman K, Davis KL, et al. Bcl-2 is a therapeutic target for Hypodiploid B-lineage acute lymphoblastic leukemia. Cancer Res. 2019;79(9):2339–51.PubMedPubMedCentralCrossRef
295.
Guy JB, Espenel S, Louati S, Gauthier A, Garcia MA, Vial N, et al. Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma. J Cancer Res Clin Oncol. 2021;147(7):1905–16.PubMedCrossRef
296.
Bate-Eya LT, den Hartog IJ, van der Ploeg I, Schild L, Koster J, Santo EE, et al. High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition. Oncotarget. 2016;7(19):27946–58.PubMedPubMedCentralCrossRef
297.
Bierbrauer A, Jacob M, Vogler M, Fulda S. A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma. Br J Cancer. 2020;122(10):1544–51.PubMedPubMedCentralCrossRef
298.
Chen J, Zhou H, Aguilar A, Liu L, Bai L, McEachern D, et al. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression. J Med Chem. 2012;55(19):8502–14.PubMedPubMedCentralCrossRef
299.
Bai L, Chen J, McEachern D, Liu L, Zhou H, Aguilar A, et al. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One. 2014;9(6):e99404.PubMedPubMedCentralCrossRef
300.
Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014;4(3):362–75.PubMedCrossRef
301.
Zhou Y, Liu H, Xue R, Tang W, Zhang S. BH3 mimetic ABT-199 enhances the sensitivity of gemcitabine in pancreatic Cancer in vitro and in vivo. Dig Dis Sci. 2018;63(12):3367–75.PubMedCrossRef
302.
Peirs S, Matthijssens F, Goossens S, Van de Walle I, Ruggero K, de Bock CE, et al. ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia. Blood. 2014;124(25):3738–47.PubMedCrossRef
303.
Niu X, Zhao J, Ma J, Xie C, Edwards H, Wang G, et al. Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with Daunorubicin or Cytarabine in AML cells. Clin Cancer Res. 2016;22(17):4440–51.PubMedPubMedCentralCrossRef
304.
Li Z, He S, Look AT. The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. Leukemia. 2019;33(1):262–6.PubMedCrossRef
305.
Shi YF, Liu L, He LL, Ye J, Lin ZJ, Yuan DL, et al. Combining triptolide with ABT-199 is effective against acute myeloid leukemia through reciprocal regulation of Bcl-2 family proteins and activation of the intrinsic apoptotic pathway. Cell Death Dis. 2020;11(7):555.PubMedPubMedCentralCrossRef
306.
Xiufeng Z, Haijun Z, Silei B, Manman D, Yong Z, Lian Y, et al. Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia. Anti-Cancer Drugs. 2019;30(2):138–48.PubMedCrossRef
307.
Wang X, Mak PY, Mu H, Tao W, Rao A, Visweswaran R, et al. Combinatorial inhibition of focal adhesion kinase and BCL-2 enhances antileukemia activity of Venetoclax in acute myeloid leukemia. Mol Cancer Ther. 2020;19(8):1636–48.PubMedPubMedCentralCrossRef
308.
Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, et al. Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24(1):120–9.PubMedCrossRef
309.
Ko TK, Chuah CT, Huang JW, Ng KP, Ong ST. The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors. Oncotarget. 2014;5(19):9033–8.PubMedPubMedCentralCrossRef
310.
Yu Z, Du J, Zhao Y, Gao Y, Li Y, Zhao K, et al. A novel kinase inhibitor, LZT-106, downregulates Mcl-1 and sensitizes colorectal cancer cells to BH3 mimetic ABT-199 by targeting CDK9 and GSK-3beta signaling. Cancer Lett. 2021;498:31–41.PubMedCrossRef
311.
Kuo HP, Ezell SA, Schweighofer KJ, Cheung LWK, Hsieh S, Apatira M, et al. Combination of Ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma. Mol Cancer Ther. 2017;16(7):1246–56.PubMedCrossRef
312.
Phillips DC, Jin S, Gregory GP, Zhang Q, Xue J, Zhao X, et al. A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies. Leukemia. 2020;34(6):1646–57.PubMedCrossRef
313.
Zhang Y, Zhou L, Bandyopadhyay D, Sharma K, Allen AJ, Kmieciak M, et al. The covalent CDK7 inhibitor THZ1 potently induces apoptosis in multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2019;25(20):6195–205.PubMedPubMedCentralCrossRef
314.
Zhou L, Zhang Y, Sampath D, Leverson J, Dai Y, Kmieciak M, et al. Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer. 2018;118(3):388–97.PubMedCrossRef
315.
Muenchow A, Weller S, Hinterleitner C, Malenke E, Bugl S, Wirths S, et al. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. Cell Death Dis. 2020;11(8):701.PubMedPubMedCentralCrossRef
316.
Zhang B, Gojo I, Fenton RG. Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood. 2002;99(6):1885–93.PubMedCrossRef
317.
Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A. 1993;90(8):3516–20.PubMedPubMedCentralCrossRef
318.
Lomo J, Smeland EB, Krajewski S, Reed JC, Blomhoff HK. Expression of the Bcl-2 homologue Mcl-1 correlates with survival of peripheral blood B lymphocytes. Cancer Res. 1996;56(1):40–3.PubMed
319.
Zhou P, Qian L, Bieszczad CK, Noelle R, Binder M, Levy NB, et al. Mcl-1 in transgenic mice promotes survival in a spectrum of hematopoietic cell types and immortalization in the myeloid lineage. Blood. 1998;92(9):3226–39.PubMedCrossRef
320.
Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967):671–6.PubMedCrossRef
321.
Perciavalle RM, Stewart DP, Koss B, Lynch J, Milasta S, Bathina M, et al. Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration. Nat Cell Biol. 2012;14(6):575–83.PubMedPubMedCentralCrossRef
322.
Fujise K, Zhang D, Liu J, Yeh ET. Regulation of apoptosis and cell cycle progression by MCL1. Differential role of proliferating cell nuclear antigen. J Biol Chem. 2000;275(50):39458–65.PubMedCrossRef
323.
Jamil S, Mojtabavi S, Hojabrpour P, Cheah S, Duronio V. An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. Mol Biol Cell. 2008;19(8):3212–20.PubMedPubMedCentralCrossRef
324.
Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MK. Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem. 2000;275(29):22136–46.PubMedCrossRef
325.
Bae J, Leo CP, Hsu SY, Hsueh AJ. MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain. J Biol Chem. 2000;275(33):25255–61.PubMedCrossRef
326.
Morciano G, Giorgi C, Balestra D, Marchi S, Perrone D, Pinotti M, et al. Mcl-1 involvement in mitochondrial dynamics is associated with apoptotic cell death. Mol Biol Cell. 2016;27(1):20–34.PubMedPubMedCentralCrossRef
327.
Kim JH, Sim SH, Ha HJ, Ko JJ, Lee K, Bae J. MCL-1ES, a novel variant of MCL-1, associates with MCL-1L and induces mitochondrial cell death. FEBS Lett. 2009;583(17):2758–64.PubMedCrossRef
328.
Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.PubMedCrossRef
329.
Fernandez-Marrero Y, Spinner S, Kaufmann T, Jost PJ. Survival control of malignant lymphocytes by anti-apoptotic MCL-1. Leukemia. 2016;30(11):2152–9.PubMedCrossRef
330.
Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol. 2006;44(1):151–7.PubMedCrossRef
331.
Lin J, Fu D, Dai Y, Lin J, Xu T. Mcl-1 inhibitor suppresses tumor growth of esophageal squamous cell carcinoma in a mouse model. Oncotarget. 2017;8(70):114457–62.PubMedPubMedCentralCrossRef
332.
Campbell KJ, Dhayade S, Ferrari N, Sims AH, Johnson E, Mason SM, et al. MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death Dis. 2018;9(2):19.PubMedPubMedCentralCrossRef
333.
Hosseini A, Espona-Fiedler M, Soto-Cerrato V, Quesada R, Perez-Tomas R, Guallar V. Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members. PLoS One. 2013;8(2):e57562.PubMedPubMedCentralCrossRef
334.
Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307(5712):1101–4.PubMedCrossRef
335.
Abdul Rahman SF, Muniandy K, Soo YK, Tiew EYH, Tan KX, Bates TE, et al. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. Biochem Biophys Rep. 2020;22:100756.PubMedPubMedCentral
336.
Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, et al. Discovery of S64315, a potent and selective Mcl-1 inhibitor. J Med Chem. 2020;63(22):13762–95.PubMedCrossRef
337.
Luedtke DA, Niu X, Pan Y, Zhao J, Liu S, Edwards H, et al. Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. Signal Transduct Target Ther. 2017;2:17012.PubMedPubMedCentralCrossRef
338.
De Blasio A, Pratelli G, Drago-Ferrante R, Saliba C, Baldacchino S, Grech G, et al. Loss of MCL1 function sensitizes the MDA-MB-231 breast cancer cells to rh-TRAIL by increasing DR4 levels. J Cell Physiol. 2019;234(10):18432–47.PubMedCrossRef
339.
Song S, Kim S, El-Sawy ER, Cerella C, Orlikova-Boyer B, Kirsch G, et al. Anti-leukemic properties of aplysinopsin derivative ee-84 alone and combined to bh3 mimetic a-1210477. Mar Drugs. 2021;19(6):285.PubMedPubMedCentralCrossRef
340.
Kawakami H, Huang S, Pal K, Dutta SK, Mukhopadhyay D, Sinicrope FA. Mutant BRAF upregulates MCL-1 to confer apoptosis resistance that is reversed by MCL-1 antagonism and Cobimetinib in colorectal Cancer. Mol Cancer Ther. 2016;15(12):3015–27.PubMedPubMedCentralCrossRef
341.
Quentmeier H, Drexler HG, Hauer V, MacLeod RA, Pommerenke C, Uphoff CC, et al. Diffuse large B cell lymphoma cell line U-2946: model for MCL1 inhibitor testing. PLoS One. 2016;11(12):e0167599.PubMedPubMedCentralCrossRef
342.
Ow TJ, Fulcher CD, Thomas C, Broin PO, Lopez A, Reyna DE, et al. Optimal targeting of BCL-family proteins in head and neck squamous cell carcinoma requires inhibition of both BCL-xL and MCL-1. Oncotarget. 2019;10(4):494–510.PubMedPubMedCentralCrossRef
343.
Phillips DC, Xiao Y, Lam LT, Litvinovich E, Roberts-Rapp L, Souers AJ, et al. Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J. 2015;5:e368.PubMedPubMedCentralCrossRef
344.
Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, et al. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res. 2020;26(14):3856–67.PubMedPubMedCentralCrossRef
345.
346.
Zheng L, Yang W, Zhang C, Ding WJ, Zhu H, Lin NM, et al. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett. 2011;309(1):27–36.PubMedCrossRef
347.
Respondek M, Beberok A, Rok J, Rzepka Z, Wrzesniok D, Buszman E. MIM1, the Mcl-1 - specific BH3 mimetic induces apoptosis in human U87MG glioblastoma cells. Toxicol in Vitro. 2018;53:126–35.PubMedCrossRef
348.
Respondek M, Beberok A, Rzepka Z, Rok J, Wrzesniok D. Mcl-1 inhibitor induces cells death in BRAF-mutant Amelanotic melanoma trough GSH depletion, DNA damage and cell cycle changes. Pathol Oncol Res. 2020;26(3):1465–74.PubMedCrossRef
349.
Respondek M, Beberok A, Rzepka Z, Rok J, Wrzesniok D. MIM1 induces COLO829 melanoma cell death through mitochondrial membrane breakdown, GSH depletion, and DNA damage. Fundam Clin Pharmacol. 2020;34(1):20–31.PubMedCrossRef
350.
Seipel K, Schmitter K, Bacher U, Pabst T. Rationale for a combination therapy consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia. Cancers (Basel). 2019;11(11):1779.CrossRef
351.
Grundy M, Balakrishnan S, Fox M, Seedhouse CH, Russell NH. Genetic biomarkers predict response to dual BCL-2 and MCL-1 targeting in acute myeloid leukaemia cells. Oncotarget. 2018;9(102):37777–89.PubMedPubMedCentralCrossRef
352.
Seipel K, Kopp B, Bacher U, Pabst T. BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers (Basel). 2021;13(3):581–96.PubMedPubMedCentralCrossRef
353.
Hormi M, Birsen R, Belhadj M, Huynh T, Cantero Aguilar L, Grignano E, et al. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Eur J Haematol. 2020;105(5):588–96.PubMedCrossRef
354.
355.
Song X, Shen L, Tong J, Kuang C, Zeng S, Schoen RE, et al. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer. Theranostics. 2020;10(18):8098–110.PubMedPubMedCentralCrossRef
356.
Prukova D, Andera L, Nahacka Z, Karolova J, Svaton M, Klanova M, et al. Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma. Clin Cancer Res. 2019;25(14):4455–65.PubMedCrossRef
357.
Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, et al. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020;11(6):443.PubMedPubMedCentralCrossRef
358.
Sarif Z, Tolksdorf B, Fechner H, Eberle J. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells. Mol Carcinog. 2020;59(11):1256–68.PubMedCrossRef
359.
Seiller C, Maiga S, Touzeau C, Bellanger C, Kervoelen C, Descamps G, et al. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes. Cell Death Dis. 2020;11(5):316.PubMedPubMedCentralCrossRef
360.
Wong KY, Chim CS. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. J Pharm Pharmacol. 2020;72(5):728–37.PubMedCrossRef
361.
Algarin EM, Diaz-Tejedor A, Mogollon P, Hernandez-Garcia S, Corchete LA, San-Segundo L, et al. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Haematologica. 2020;105(3):e116–20.PubMedPubMedCentralCrossRef
362.
Williams MM, Elion DL, Rahman B, Hicks DJ, Sanchez V, Cook RS. Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers. Oncotarget. 2019;10(52):5389–402.PubMedPubMedCentralCrossRef
363.
Lu X, Liang H, Orvig C, Chen ZF. Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents. Curr Mol Med. 2021;21(5):426–39.PubMedCrossRef
364.
Wei AH, Roberts AW, Spencer A, Rosenberg AS, Siegel D, Walter RB, et al. Targeting MCL-1 in hematologic malignancies: rationale and progress. Blood Rev. 2020;44:100672.PubMedPubMedCentralCrossRef
365.
Zhang H, Nakauchi Y, Kohnke T, Stafford M, Bottomly D, Thomas R, et al. Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia. Nat Cancer. 2020;1(8):826–39.PubMedPubMedCentralCrossRef
366.
Arulananda S, O'Brien M, Evangelista M, Jenkins LJ, Poh AR, Walkiewicz M, et al. A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma. Cell Death Discov. 2021;7(1):122.PubMedPubMedCentralCrossRef
367.
Letai A. S63845, an MCL-1 selective BH3 mimetic: another arrow in our quiver. Cancer Cell. 2016;30(6):834–5.PubMedCrossRef
368.
Bala Tannan N, Manzari MT, Herviou L, Da Silva FM, Hagen C, Kiguchi H, et al. Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition. Blood. 2021;137(15):2057–69.PubMedPubMedCentralCrossRef
369.
Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, et al. MCL-1 dependency of cisplatin-resistant cancer cells. Biochem Pharmacol. 2014;92(1):55–61.PubMedCrossRef
370.
Tromp JM, Geest CR, Breij EC, Elias JA, van Laar J, Luijks DM, et al. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia. Clin Cancer Res. 2012;18(2):487–98.PubMedCrossRef
371.
Bates DJ, Danilov AV, Lowrey CH, Eastman A. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737. Mol Cancer Ther. 2013;12(8):1504–14.PubMedPubMedCentralCrossRef
372.
Jane EP, Premkumar DR, Cavaleri JM, Sutera PA, Rajasekar T, Pollack IF. Dinaciclib, a cyclin-dependent kinase inhibitor promotes proteasomal degradation of Mcl-1 and enhances ABT-737-mediated cell death in malignant human glioma cell lines. J Pharmacol Exp Ther. 2016;356(2):354–65.PubMedPubMedCentralCrossRef
373.
Sulkshane P, Teni T. BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells. Oncotarget. 2017;8(36):60060–79.PubMedCrossRef
374.
375.
Robin AY, Krishna Kumar K, Westphal D, Wardak AZ, Thompson GV, Dewson G, et al. Crystal structure of Bax bound to the BH3 peptide of Bim identifies important contacts for interaction. Cell Death Dis. 2015;6:e1809.PubMedPubMedCentralCrossRef
376.
Garner TP, Reyna DE, Priyadarshi A, Chen HC, Li S, Wu Y, et al. An autoinhibited dimeric form of BAX regulates the BAX activation pathway. Mol Cell. 2016;63(3):485–97.PubMedPubMedCentralCrossRef
377.
Hadji A, Schmitt GK, Schnorenberg MR, Roach L, Hickey CM, Leak LB, et al. Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide. Oncotarget. 2019;10(58):6219–33.PubMedPubMedCentralCrossRef
378.
Lee EF, Czabotar PE, van Delft MF, Michalak EM, Boyle MJ, Willis SN, et al. A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. J Cell Biol. 2008;180(2):341–55.PubMedPubMedCentralCrossRef
379.
Kritzer JA. The secret of MIM: a novel, MCL-1-specific small molecule. Chem Biol. 2012;19(9):1082–3.PubMedCrossRef
380.
Trudel S, Li ZH, Rauw J, Tiedemann RE, Wen XY, Stewart AK. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood. 2007;109(12):5430–8.PubMedCrossRef
381.
Zhang M, Liu H, Guo R, Ling Y, Wu X, Li B, et al. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem Pharmacol. 2003;66(1):93–103.PubMedCrossRef
382.
Certo M, Del Gaizo MV, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006;9(5):351–65.PubMedCrossRef
383.
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, et al. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019;25(12):1938–47.PubMedPubMedCentralCrossRef
384.
Dutta S, Ryan J, Chen TS, Kougentakis C, Letai A, Keating AE. Potent and specific peptide inhibitors of human pro-survival protein Bcl-xL. J Mol Biol. 2015;427(6 Pt B):1241–53.PubMedCrossRef
385.
Mitchell WB, Pinheiro MP, Boulad N, Kaplan D, Edison MN, Psaila B, et al. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia. Am J Hematol. 2014;89(12):E228–34.PubMedCrossRef
386.
387.
Suvarna V, Singh V, Murahari M. Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. Eur J Pharmacol. 2019;862:172655.PubMedCrossRef
388.
Xiong H, Pradhan RS, Nada A, Krivoshik AP, Holen KD, Rhodes JW, et al. Studying navitoclax, a targeted anticancer drug, in healthy volunteers--ethical considerations and risk/benefit assessments and management. Anticancer Res. 2014;34(7):3739–46.PubMed
389.
Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11(12):1149–59.PubMedPubMedCentralCrossRef
390.
Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol. 2011;29(7):909–16.PubMedPubMedCentralCrossRef
391.
Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30(5):488–96.PubMedCrossRef
392.
Puglisi M, Molife LR, de Jonge MJ, Khan KH, Doorn LV, Forster MD, et al. A phase I study of the safety, pharmacokinetics and efficacy of navitoclax plus docetaxel in patients with advanced solid tumors. Future Oncol. 2021;17(21):2747–58.PubMedCrossRef
393.
Tolcher AW, LoRusso P, Arzt J, Busman TA, Lian G, Rudersdorf NS, et al. Safety, efficacy, and pharmacokinetics of navitoclax (ABT-263) in combination with erlotinib in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2015;76(5):1025–32.PubMedCrossRef
394.
Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, et al. A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Investig New Drugs. 2014;32(5):937–45.CrossRef
395.
Vlahovic G, Karantza V, Wang D, Cosgrove D, Rudersdorf N, Yang J, et al. A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors. Investig New Drugs. 2014;32(5):976–84.CrossRef
396.
397.
de Vos S, Leonard JP, Friedberg JW, Zain J, Dunleavy K, Humerickhouse R, et al. Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leuk Lymphoma. 2021;62(4):810–8.PubMedCrossRef
398.
Yang J, Pradhan RS, Rosen LS, Graham AM, Holen KD, Xiong H. Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-XL , in patients with cancer. J Clin Pharm Ther. 2014;39(6):680–4.PubMedCrossRef
399.
Roberts AW, Advani RH, Kahl BS, Persky D, Sweetenham JW, Carney DA, et al. Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies. Br J Haematol. 2015;170(5):669–78.PubMedPubMedCentralCrossRef
400.
Kipps TJ, Eradat H, Grosicki S, Catalano J, Cosolo W, Dyagil IS, et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2015;56(10):2826–33.PubMedPubMedCentralCrossRef
401.
Stein MN, Goodin S, Gounder M, Gibbon D, Moss R, Portal D, et al. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Investig New Drugs. 2020;38(3):855–65.CrossRef
402.
Vogler M, Weber K, Dinsdale D, Schmitz I, Schulze-Osthoff K, Dyer MJ, et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ. 2009;16(7):1030–9.PubMedCrossRef
403.
Wroblewski D, Jiang CC, Croft A, Farrelly ML, Zhang XD, Hersey P. OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. PLoS One. 2013;8(12):e84073.PubMedPubMedCentralCrossRef
404.
Heidari N, Hicks MA, Harada H. GX15-070 (obatoclax) overcomes glucocorticoid resistance in acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis. 2010;1:e76.PubMedPubMedCentralCrossRef
405.
Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, et al. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood. 2013;121(14):2689–703.PubMedPubMedCentralCrossRef
406.
Basit F, Cristofanon S, Fulda S. Obatoclax (GX15-070) triggers necroptosis by promoting the assembly of the necrosome on autophagosomal membranes. Cell Death Differ. 2013;20(9):1161–73.PubMedPubMedCentralCrossRef
407.
Su JC, Chen KF, Chen WL, Liu CY, Huang JW, Tai WT, et al. Synthesis and biological activity of obatoclax derivatives as novel and potent SHP-1 agonists. Eur J Med Chem. 2012;56:127–33.PubMedCrossRef
408.
Schimmer AD, Raza A, Carter TH, Claxton D, Erba H, DeAngelo DJ, et al. A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia. PLoS One. 2014;9(10):e108694.PubMedPubMedCentralCrossRef
409.
Langer CJ, Albert I, Ross HJ, Kovacs P, Blakely LJ, Pajkos G, et al. Randomized phase II study of carboplatin and etoposide with or without obatoclax mesylate in extensive-stage small cell lung cancer. Lung Cancer. 2014;85(3):420–8.PubMedCrossRef
410.
Arellano ML, Borthakur G, Berger M, Luer J, Raza A. A phase II, multicenter, open-label study of obatoclax mesylate in patients with previously untreated myelodysplastic syndromes with anemia or thrombocytopenia. Clin Lymphoma Myeloma Leuk. 2014;14(6):534–9.PubMedCrossRef
411.
Oki Y, Copeland A, Hagemeister F, Fayad LE, Fanale M, Romaguera J, et al. Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma. Blood. 2012;119(9):2171–2.PubMedCrossRef
412.
Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer. 2011;74(3):481–5.PubMedCrossRef
413.
Parikh SA, Kantarjian H, Schimmer A, Walsh W, Asatiani E, El-Shami K, et al. Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010;10(4):285–9.PubMedCrossRef
414.
O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009;113(2):299–305.PubMedPubMedCentralCrossRef
415.
Schimmer AD, O'Brien S, Kantarjian H, Brandwein J, Cheson BD, Minden MD, et al. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin Cancer Res. 2008;14(24):8295–301.PubMedCrossRef
416.
417.
Goy A, Hernandez-Ilzaliturri FJ, Kahl B, Ford P, Protomastro E, Berger M. A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leuk Lymphoma. 2014;55(12):2761–8.PubMedPubMedCentralCrossRef
418.
Infante JR, Dees EC, Olszanski AJ, Dhuria SV, Sen S, Cameron S, et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014;32(28):3103–10.PubMedCrossRef
419.
Ikeda F, Deribe YL, Skanland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, et al. SHARPIN forms a linear ubiquitin ligase complex regulating NF-kappaB activity and apoptosis. Nature. 2011;471(7340):637–41.PubMedPubMedCentralCrossRef
420.
Gerlach B, Cordier SM, Schmukle AC, Emmerich CH, Rieser E, Haas TL, et al. Linear ubiquitination prevents inflammation and regulates immune signalling. Nature. 2011;471(7340):591–6.PubMedCrossRef
421.
Tokunaga F, Nakagawa T, Nakahara M, Saeki Y, Taniguchi M, Sakata S, et al. SHARPIN is a component of the NF-kappaB-activating linear ubiquitin chain assembly complex. Nature. 2011;471(7340):633–6.PubMedCrossRef
422.
Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat Biotechnol. 2014;32(2):182–90.PubMedPubMedCentralCrossRef
423.
Borthakur G, Odenike O, Aldoss I, Rizzieri DA, Prebet T, Chen C, et al. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer. 2021;127(16):2943–53.PubMedCrossRef
424.
Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, et al. First-in-human study of Mivebresib (ABBV-075), an Oral Pan-inhibitor of Bromodomain and extra terminal proteins, in patients with relapsed/refractory solid tumors. Clin Cancer Res. 2019;25(21):6309–19.PubMedCrossRef
425.
Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illes A, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600–9.PubMedPubMedCentralCrossRef
426.
Zelenetz AD, Salles G, Mason KD, Casulo C, Le Gouill S, Sehn LH, et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood. 2019;133(18):1964–76.PubMedPubMedCentralCrossRef
427.
Zinzani PL, Flinn IW, Yuen SLS, Topp MS, Rusconi C, Fleury I, et al. Venetoclax-rituximab with or without bendamustine vs bendamustine-rituximab in relapsed/refractory follicular lymphoma. Blood. 2020;136(23):2628–37.PubMedPubMedCentral
428.
Izutsu K, Yamamoto K, Kato K, Ishikawa T, Fukuhara N, Terui Y, et al. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Int J Hematol. 2021;113(3):370–80.PubMedCrossRef
429.
Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, et al. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood. 2019;133(26):2765–75.PubMedPubMedCentralCrossRef
430.
Wei AH, Strickland SA Jr, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose Cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib/II study. J Clin Oncol. 2019;37(15):1277–84.PubMedPubMedCentralCrossRef
431.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and Venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380(22):2095–103.PubMedCrossRef
432.
de Vos S, Swinnen LJ, Wang D, Reid E, Fowler N, Cordero J, et al. Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study. Ann Oncol. 2018;29(9):1932–8.PubMedPubMedCentralCrossRef
433.
Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107–20.PubMedCrossRef
434.
Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, Al-Sawaf O, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215–28.PubMedCrossRef
435.
Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22.PubMedCrossRef
436.
Barr PM, Robak T, Owen C, Tedeschi A, Bairey O, Bartlett NL, et al. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica. 2018;103(9):1502–10.PubMedPubMedCentralCrossRef
437.
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.PubMedPubMedCentralCrossRef
438.
Cartron G, de Guibert S, Dilhuydy MS, Morschhauser F, Leblond V, Dupuis J, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124(14):2196–202.PubMedCrossRef
439.
Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2):169–76.PubMedCrossRef
440.
Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. 2017;130(22):2392–400.PubMedCrossRef
441.
Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768–78.PubMedCrossRef
442.
Stilgenbauer S, Eichhorst B, Schetelig J, Hillmen P, Seymour JF, Coutre S, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial. J Clin Oncol. 2018;36(19):1973–80.PubMedCrossRef
443.
Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134(2):111–22.PubMedPubMedCentralCrossRef
444.
Konopleva M, Pollyea DA, Potluri J, Chyla B, Hogdal L, Busman T, et al. Efficacy and biological correlates of response in a phase II study of Venetoclax monotherapy in patients with acute myelogenous leukemia. Cancer Discov. 2016;6(10):1106–17.PubMedPubMedCentralCrossRef
445.
Leverson JD, Sampath D, Souers AJ, Rosenberg SH, Fairbrother WJ, Amiot M, et al. Found in translation: how preclinical research is guiding the clinical development of the BCL2-selective inhibitor Venetoclax. Cancer Discov. 2017;7(12):1376–93.PubMedPubMedCentralCrossRef
446.
Davids MS, Roberts AW, Seymour JF, Pagel JM, Kahl BS, Wierda WG, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826–33.PubMedPubMedCentralCrossRef
447.
Roberts AW, Huang D. Targeting BCL2 with BH3 mimetics: basic science and clinical application of Venetoclax in chronic lymphocytic leukemia and related B cell malignancies. Clin Pharmacol Ther. 2017;101(1):89–98.PubMedCrossRef
448.
Ruefli-Brasse A, Reed JC. Therapeutics targeting Bcl-2 in hematological malignancies. Biochem J. 2017;474(21):3643–57.PubMedCrossRef
449.
Seymour JF, Ma S, Brander DM, Choi MY, Barrientos J, Davids MS, et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study. Lancet Oncol. 2017;18(2):230–40.PubMedPubMedCentralCrossRef
450.
Zhang H, Guttikonda S, Roberts L, Uziel T, Semizarov D, Elmore SW, et al. Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines. Oncogene. 2011;30(16):1963–8.PubMedCrossRef
451.
Xiao Y, Nimmer P, Sheppard GS, Bruncko M, Hessler P, Lu X, et al. MCL-1 is a key determinant of breast Cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor. Mol Cancer Ther. 2015;14(8):1837–47.PubMedCrossRef
452.
Yecies D, Carlson NE, Deng J, Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood. 2010;115(16):3304–13.PubMedPubMedCentralCrossRef
453.
Wei SH, Dong K, Lin F, Wang X, Li B, Shen JJ, et al. Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell. Cancer Chemother Pharmacol. 2008;62(6):1055–64.PubMedCrossRef
454.
Wertz IE, Kusam S, Lam C, Okamoto T, Sandoval W, Anderson DJ, et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature. 2011;471(7336):110–4.PubMedCrossRef
455.
Akagi H, Higuchi H, Sumimoto H, Igarashi T, Kabashima A, Mizuguchi H, et al. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer. 2013;16(1):100–10.PubMedCrossRef
456.
Thomas RL, Roberts DJ, Kubli DA, Lee Y, Quinsay MN, Owens JB, et al. Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. Genes Dev. 2013;27(12):1365–77.PubMedPubMedCentralCrossRef
457.
Vick B, Weber A, Urbanik T, Maass T, Teufel A, Krammer PH, et al. Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes. Hepatology. 2009;49(2):627–36.PubMedCrossRef
458.
Arbour N, Vanderluit JL, Le Grand JN, Jahani-Asl A, Ruzhynsky VA, Cheung EC, et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J Neurosci. 2008;28(24):6068–78.PubMedPubMedCentralCrossRef
459.
Opferman JT, Kothari A. Anti-apoptotic BCL-2 family members in development. Cell Death Differ. 2018;25(1):37–45.PubMedCrossRef
460.
Lee EF, Czabotar PE, Yang H, Sleebs BE, Lessene G, Colman PM, et al. Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands. J Biol Chem. 2009;284(44):30508–17.PubMedPubMedCentralCrossRef
461.
Abulwerdi F, Liao C, Liu M, Azmi AS, Aboukameel A, Mady AS, et al. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther. 2014;13(3):565–75.PubMedCrossRef
462.
Ji T, Ding Y, Zhao Y, Wang J, Qin H, Liu X, et al. Peptide assembly integration of fibroblast-targeting and cell-penetration features for enhanced antitumor drug delivery. Adv Mater. 2015;27(11):1865–73.PubMedCrossRef
463.
Soukasene S, Toft DJ, Moyer TJ, Lu H, Lee HK, Standley SM, et al. Antitumor activity of peptide amphiphile nanofiber-encapsulated camptothecin. ACS Nano. 2011;5(11):9113–21.PubMedPubMedCentralCrossRef
464.
Ben-Nun Y, Fichman G, Adler-Abramovich L, Turk B, Gazit E, Blum G. Cathepsin nanofiber substrates as potential agents for targeted drug delivery. J Control Release. 2017;257:60–7.PubMedCrossRef
465.
466.
Lin R, Cheetham AG, Zhang P, Lin YA, Cui H. Supramolecular filaments containing a fixed 41% paclitaxel loading. Chem Commun (Camb). 2013;49(43):4968–70.CrossRef
467.
Chen Z, Xing L, Fan Q, Cheetham AG, Lin R, Holt B, et al. Drug-bearing supramolecular filament hydrogels as anti-inflammatory agents. Theranostics. 2017;7(7):2003–14.PubMedPubMedCentralCrossRef
468.
Mazza M, Hadjidemetriou M, de Lazaro I, Bussy C, Kostarelos K. Peptide nanofiber complexes with siRNA for deep brain gene silencing by stereotactic neurosurgery. ACS Nano. 2015;9(2):1137–49.PubMedCrossRef
469.
Lock LL, Li Y, Mao X, Chen H, Staedtke V, Bai R, et al. One-component supramolecular filament hydrogels as Theranostic label-free magnetic resonance imaging agents. ACS Nano. 2017;11(1):797–805.PubMedPubMedCentralCrossRef
470.
Lock LL, Reyes CD, Zhang P, Cui H. Tuning cellular uptake of molecular probes by rational Design of Their Assembly into supramolecular Nanoprobes. J Am Chem Soc. 2016;138(10):3533–40.PubMedCrossRef
471.
Li Y, Lock LL, Wang Y, Ou SH, Stern D, Schon A, et al. Bioinspired supramolecular engineering of self-assembling immunofibers for high affinity binding of immunoglobulin G. Biomaterials. 2018;178:448–57.PubMedCrossRef
472.
Zhang X, Xu X, Li Y, Hu C, Zhang Z, Gu Z. Virion-like membrane-breaking nanoparticles with tumor-activated cell-and-tissue dual-penetration conquer impermeable cancer. Adv Mater. 2018;30(27):e1707240.PubMedCrossRef
473.
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51.PubMedPubMedCentralCrossRef
474.
Newcomb CJ, Sur S, Ortony JH, Lee OS, Matson JB, Boekhoven J, et al. Cell death versus cell survival instructed by supramolecular cohesion of nanostructures. Nat Commun. 2014;5:3321.PubMedCrossRef
475.
Schnorenberg MR, Bellairs JA, Samaeekia R, Acar H, Tirrell MV, JL LB. Activating the intrinsic pathway of apoptosis using bim bh3 peptides delivered by peptide amphiphiles with endosomal release. Materials (Basel). 2019;12(16):2567.CrossRef
476.
Missirlis D, Teesalu T, Black M, Tirrell M. The non-peptidic part determines the internalization mechanism and intracellular trafficking of peptide amphiphiles. PLoS One. 2013;8(1):e54611.PubMedPubMedCentralCrossRef
477.
Acar H, Ting JM, Srivastava S, LaBelle JL, Tirrell MV. Molecular engineering solutions for therapeutic peptide delivery. Chem Soc Rev. 2017;46(21):6553–69.PubMedCrossRef
478.
Meyer DE, Kong GA, Dewhirst MW, Zalutsky MR, Chilkoti A. Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia. Cancer Res. 2001;61(4):1548–54.PubMed
479.
Dreher MR, Liu W, Michelich CR, Dewhirst MW, Chilkoti A. Thermal cycling enhances the accumulation of a temperature-sensitive biopolymer in solid tumors. Cancer Res. 2007;67(9):4418–24.PubMedCrossRef
480.
Liu W, Dreher MR, Furgeson DY, Peixoto KV, Yuan H, Zalutsky MR, et al. Tumor accumulation, degradation and pharmacokinetics of elastin-like polypeptides in nude mice. J Control Release. 2006;116(2):170–8.PubMedCrossRef
481.
Issels RD. Regional hyperthermia combined with systemic chemotherapy of locally advanced sarcomas: preclinical aspects and clinical results. Recent Results Cancer Res. 1995;138:81–90.PubMedCrossRef
482.
Feyerabend T, Steeves R, Wiedemann GJ, Richter E, Robins HI. Rationale and clinical status of local hyperthermia, radiation, and chemotherapy in locally advanced malignancies. Anticancer Res. 1997;17(4B):2895–7.PubMed
483.
van Vulpen M, Raaymakers BW, de Leeuw AA, van de Kamer JB, van Moorselaar RJ, Hobbelink MG, et al. Prostate perfusion in patients with locally advanced prostate carcinoma treated with different hyperthermia techniques. J Urol. 2002;168(4 Pt 1):1597–602.PubMedCrossRef
484.
Issels RD. Regional hyperthermia in high-risk soft tissue sarcomas. Curr Opin Oncol. 2008;20(4):438–43.PubMedCrossRef
485.
Dinca A, Chien WM, Chin MT. Intracellular delivery of proteins with cell-penetrating peptides for therapeutic uses in human disease. Int J Mol Sci. 2016;17(2):263.PubMedPubMedCentralCrossRef
486.
Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol. 2001;19(12):1173–6.PubMedCrossRef
487.
Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285(5433):1569–72.PubMedCrossRef
488.
Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J Neurosci. 2002;22(13):5423–31.PubMedPubMedCentralCrossRef
489.
Andreev OA, Engelman DM, Reshetnyak YK. Targeting acidic diseased tissue: new technology based on use of the pH (low) insertion peptide (pHLIP). Chim Oggi. 2009;27(2):34–7.PubMedPubMedCentral
490.
Andreev OA, Engelman DM, Reshetnyak YK. pH-sensitive membrane peptides (pHLIPs) as a novel class of delivery agents. Mol Membr Biol. 2010;27(7):341–52.PubMedPubMedCentralCrossRef
491.
Deacon JC, Engelman DM, Barrera FN. Targeting acidity in diseased tissues: mechanism and applications of the membrane-inserting peptide, pHLIP. Arch Biochem Biophys. 2015;565:40–8.PubMedCrossRef
492.
Banerjee A, Onyuksel H. Peptide delivery using phospholipid micelles. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2012;4(5):562–74.PubMedCrossRef
493.
Guo J, Wu T, Ping Q, Chen Y, Shen J, Jiang G. Solubilization and pharmacokinetic behaviors of sodium cholate/lecithin-mixed micelles containing cyclosporine a. Drug Deliv. 2005;12(1):35–9.PubMedCrossRef
494.
Onyuksel H, Jeon E, Rubinstein I. Nanomicellar paclitaxel increases cytotoxicity of multidrug resistant breast cancer cells. Cancer Lett. 2009;274(2):327–30.PubMedCrossRef
495.
Lim SB, Rubinstein I, Sadikot RT, Artwohl JE, Onyuksel H. A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. Pharm Res. 2011;28(3):662–72.PubMedCrossRef
496.
Krishnadas A, Onyuksel H, Rubinstein I. Interactions of VIP, secretin and PACAP(1-38) with phospholipids: a biological paradox revisited. Curr Pharm Des. 2003;9(12):1005–12.PubMedCrossRef
497.
Onyuksel H, Sejourne F, Suzuki H, Rubinstein I. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension. Peptides. 2006;27(9):2271–5.PubMedCrossRef
498.
Kuzmis A, Lim SB, Desai E, Jeon E, Lee BS, Rubinstein I, et al. Micellar nanomedicine of human neuropeptide Y. Nanomedicine. 2011;7(4):464–71.PubMedCrossRef
499.
500.
Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4):389–427.PubMedCrossRef
501.
Liu S, Pan J, Liu J, Ma Y, Qiu F, Mei L, et al. Dynamically PEGylated and borate-coordination-polymer-coated Polydopamine nanoparticles for synergetic tumor-targeted, Chemo-Photothermal Combination Therapy. Small. 2018;14(13):e1703968.PubMedCrossRef
502.
Choi JY, Gupta B, Ramasamy T, Jeong JH, Jin SG, Choi HG, et al. PEGylated polyaminoacid-capped mesoporous silica nanoparticles for mitochondria-targeted delivery of celastrol in solid tumors. Colloids Surf B Biointerfaces. 2018;165:56–66.PubMedCrossRef
503.
Tomoda K, Chiang HC, Kozak KR, Kwon GS. Injectable (−)-gossypol-loaded Pluronic P85 micelles for cancer chemoradiotherapy. Int J Radiat Biol. 2017;93(4):402–6.PubMedCrossRef
504.
505.
Chen S, Ren Y, Duan P. Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling. Biomed Pharmacother. 2020;129:110371.PubMedCrossRef
506.
Oakes SA, Scorrano L, Opferman JT, Bassik MC, Nishino M, Pozzan T, et al. Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2005;102(1):105–10.PubMedCrossRef
507.
Maiuri MC, Criollo A, Tasdemir E, Vicencio JM, Tajeddine N, Hickman JA, et al. BH3-only proteins and BH3 mimetics induce autophagy by competitively disrupting the interaction between Beclin 1 and Bcl-2/Bcl-X(L). Autophagy. 2007;3(4):374–6.PubMedCrossRef
508.
Pedro JM, Wei Y, Sica V, Maiuri MC, Zou Z, Kroemer G, et al. BAX and BAK1 are dispensable for ABT-737-induced dissociation of the BCL2-BECN1 complex and autophagy. Autophagy. 2015;11(3):452–9.PubMedPubMedCentralCrossRef
509.
Koehler BC, Scherr AL, Lorenz S, Elssner C, Kautz N, Welte S, et al. Pan-Bcl-2 inhibitor obatoclax delays cell cycle progression and blocks migration of colorectal cancer cells. PLoS One. 2014;9(9):e106571.PubMedPubMedCentralCrossRef
510.
Zhong D, Gu C, Shi L, Xun T, Li X, Liu S, et al. Obatoclax induces G1/G0-phase arrest via p38/p21(waf1/Cip1) signaling pathway in human esophageal cancer cells. J Cell Biochem. 2014;115(9):1624–35.PubMedCrossRef
Metadata
Title
BH3-mimetics: recent developments in cancer therapy
Authors
Paul A. Townsend
Maria V. Kozhevnikova
Olivier N. F. Cexus
Andrey A. Zamyatnin Jr
Surinder M. Soond
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2021
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02157-5

Other articles of this Issue 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Go to the issue

Research

Group III phospholipase A2 downregulation attenuated survival and metastasis in ovarian cancer and promotes chemo-sensitization

Research

Inhibition of DEC2 is necessary for exiting cell dormancy in salivary adenoid cystic carcinoma

Correction

Correction to: Pyroptosis: a new paradigm of cell death for fighting against cancer

Research

NOX1 inhibition attenuates the development of a pro‐tumorigenic environment in experimental hepatocellular carcinoma

Research

TMPRSS4 promotes cancer stem–like properties in prostate cancer cells through upregulation of SOX2 by SLUG and TWIST1

Research

Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits